What type of study is this?

September 24, 2025Open Access

Nirsevimab Administration and RSV Hospitalization in the 2024-2025 Season

Key Points

Nirsevimab administration reduces hospitalization rates for respiratory syncytial virus in infants during the RSV season.
Hospitalization rates were significantly lower among infant participants receiving nirsevimab in the cohort study.
This cohort study tracked hospitalization-related data throughout the 2024-2025 season among infants.
Findings suggest that nirsevimab may play a crucial role in RSV prevention for vulnerable infant populations.

Abstract

This cohort study examines rates of hospitalization associated with respiratory syncytial virus (RSV) among infants by nirsevimab administration during the 2024-2025 season.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Jonathan Pelletier

Sarah Rush

Eric D. Robinette

Journals

JAMA Network Open

Actions

Institutions

Nationwide Children's Hospital

Children's Hospital of Pittsburgh

Northeast Ohio Medical University

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Nirsevimab Administration and RSV Hospitalization in the 2024-2025 Season

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study